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Background: Hippotherapy is a form of therapeutic riding which is used in the treatment of neurological
and muscular disorders. Until now there has not been any high-quality randomised study that has
proven its effectiveness.
Objective: The aims of this study are to evaluate whether hippotherapy (as add-on to physiotherapy and/
or pharmacotherapy) is superior to the standard treatment (physiotherapy and/or pharmacotherapy as
prior to the study) in terms of balance function and other patient relevant outcomes in patients with
multiple sclerosis.
Methods: The MS-HIPPO study is a prospective, randomised, examiner-blinded, controlled multicentre
study. Patients were randomised to one of two groups: 12 weeks of hippotherapy accompanied by
physiotherapy and/or pharmacotherapy (intervention) or 12 weeks of physiotherapy and/or pharma-
cotherapy as prior to the study (control). The primary endpoint is the change in balance function, as
measured by the Berg Balance Scale (BBS). The treatment comparison is evaluated using a covariance
analysis with baseline BBS, centre, age, gender and EDSS as covariates. Secondary endpoints include
fatigue, quality of life, pain intensity and spasticity.
Results and conclusions: The described study is the ﬁrst randomised study evaluating the beneﬁts of
hippotherapy for patients with multiple sclerosis. In 5 national centres ten study physicians will screen
potential participants. The expected results will help to improve the knowledge on non-pharmaceutical
therapeutic options in this ﬁeld.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hippotherapy, also known as equine therapy, is a form of ther-
apeutic riding. It is a one-on-one physiotherapy treatment with and
on the horse for children and adults with neurological and
muscular disorders.
Hippotherapy is mainly used in the treatment of neurological
movement and muscular disorders. Along with infantile cerebral
palsy (ICP), multiple sclerosis (MS) constitutes the main indicationics and Clinical Epidemology
0935 Cologne, Germany.
. Wollenweber).
Inc. This is an open access article ufor hippotherapy.
Though the term “hippotherapy” is not legally protected in
Germany, the concept of hippotherapy may vary depending on the
provider of therapeutic riding. Yet, the leading provider of profes-
sional qualiﬁcations is the German Consortium for Therapeutic
Riding (Deutsches Kuratorium für Therapeutisches Reiten e.V.,
DKThR). The therapy in Germany shall take place in accordance
with the guidelines for hippotherapy of the DKThR. They imply that
the horse is led on a long rein by a horse leader walking behind the
therapy horse. A hippotherapist walks beside the therapy horse and
can be supported by an assistant [1].
In Germany, 67 centres with approximately 1.600 qualiﬁed
hippotherapists offer hippotherapy according to the abovender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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covered [3].
During hippotherapy, more than 100 three-dimensional vibra-
tion pulses per minute are transmitted to the patient when the
horse is led at awalking pacewith the patient sitting upright on the
horse. In addition to this neuromotor approach, the children and
adults sense the body of the horse during the therapy session. That
induces learning (sensorimotor approach). The horse has a psy-
chomental effect on the patients (psychomotor and sociomotor
approach).
The primary goals of hippotherapy are to regulate muscle tone
(reduction of spasticity) and breathing, to strengthen the torso
muscles, and to improve balance control, coordination and gait as
well as symmetry. Furthermore, hippotherapy promotes social
communication and joy in life and strengthens self-esteem [4].
Although there have been reports of a possible effectiveness of
hippotherapy on symptoms of MS since 1978 [5], until now there
has not been any randomised controlled study that has proven the
effectiveness of hippotherapy.
This study is based on the results of two prior monocentric pilot
studies [6,7] which were carried out by the Zentrum für Ther-
apeutisches Reiten Johannisberg e.V. These two pilot studies indi-
cated that hippotherapy might provide a better outcome with
respect to balance, spasticity, quality of life and pain. We therefore
decided to choose these four endpoints and, in addition, fatigue.Fig. 1. StudyThe aim of this study is to investigate the effects of hippo-
therapy on symptoms of patients with multiple sclerosis. It thus
represents a trial that aims to prove the feasibility and effec-
tiveness of hippotherapy in a real-world setting based on its
efﬁcacy.
2. Participants and methods
2.1. Design
The study design (see Fig. 1) presented here is a prospective,
randomised, examiner-blinded, multicentre study with two paral-
lel groups.
The underlying study design enables a parallel group compari-
son after 12 weeks and conclusions about the effectiveness of
hippotherapy (as add-on to physiotherapy and/or pharmaco-
therapy) as compared to the standard treatment (physiotherapy
and/or pharmacotherapy as prior to the study).
The patients of the intervention group are to receive hippo-
therapy once a week over a period of 12 weeks as an add-on
therapy to the previous physiotherapy and/or pharmaco-
therapy; the patients of the control group shall continue their
previous physiotherapy and/or pharmacotherapy as well without
hippotherapy. As physiotherapy is reimbursed in accordance with
uniform regulations within the German statutory healthdesign.
Table 1
Study centres.
Study centre Central contact
1 Centre for Therapeutic Riding Johannisberg e.V., Windhagen Neubauer, Marie-Louise
2 Gut Uettingshof, Bad Mergentheim Dr. Kaplirz zu Sulewicz, Sabine
3 Centre for Therapeutic Riding, Nuetzen Kos-Luebben, Maren
4 Carolinenhof, Essen Braun, Sibylle A.
5 Kastanienhof, Frankfurt-Kalbach Jaeger, Susanne
Table 2
Requirements for the study centres.
 DKThR-certiﬁed facility
 Implementation of hippotherapy according to DKThR guidelines
 Designation of the head hippotherapist and his/her deputy
 Designation of the responsible physiotherapist and his/her deputy
 Separate room for the initial, interim, and ﬁnal assessments
 At least 2 therapy horses must be available for the therapy
 At least 6 patients must be treated per week
 Comprehensive cooperation with the monitor
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assume that both groups are similar in terms of the volume of
physiotherapy.
The study physician has the task to inform prospective partici-
pants about the course and possible risks of the study, to clarify the
inclusion and exclusion criteria, and to provide the consent form. In
the case of suitability, the signed consent form must be submitted
to the relevant study centre. Any tests to assess the status of pa-
tients at the beginning and throughout the study (interim and ﬁnal
assessment of patients) are performed by physiotherapists who are
blinded. After the initial test the participants of the intervention
group shall begin with the ﬁrst therapy unit.
The participants of the control group shall be offered four
“reward” hippotherapy sessions after the end of the 12-week
observation period, this is intended as a motivation for the con-
trol group to show up and participate in the examinations.Table 3
Inclusion criteria.
 Conﬁrmed multiple sclerosis with spasticity of the lower limbs
 EDSS score between 4 and 6.5
 Written informed consent of the patient
 Approval of the responsible study physician
 Legal competence
 Minimum age of 18 years
Table 4
Exclusion criteria.
 Hippotherapy within the last 12 months
 Parallel participation in other interventional trials
 Persons, who are in a dependent/working relationship with the funder or investigat
 Stay in an institution due to a court or administrative order
 Body weight over 90 kg
 Acute exacerbation during the four-week period before the start of the therapy
 No balance while sitting
 Planned start of treatment with new anti-spastic drugs or with medications that
administration of baclofen; 4-aminopyridine)
 Seizure disorders not controlled with drugs
 No or insufﬁcient capability to spread the legs so that the patient can sit on the hor
 Known severe osteoporosis
 Known severe osteoarthritis of the hip
 Known severe scoliosis, which could be made worse by hippotherapy
 Severe disorders of blood coagulation, posing the risk of hematoma due to the hipp
 Insufﬁciently stable secondary diseases in the areas of internal medicine, gynecolog
 Insurmountable fear of horses
 Horse hair allergy
 Pregnancy2.2. Study population
All patients, who meet the inclusion and exclusion criteria, are
to participate in the study and are to be randomly assigned to the
intervention or control group.
2.3. Trial centres
Patients are to be enrolled at ﬁve centres in Germany (see
Table 1). Ten study physicians will screen potential participants.
The participating centres have to meet the following pre-deﬁned
requirements: see Table 2.
2.4. Inclusion and exclusion criteria
(see Tables 3 and 4).or
may have an inﬂuence on the test parameters (examples: Sativex®; neuraxial
se
otherapy
y and/or surgery
Table 5
Berg balance scale.
Score (0e4)
1 Sitting to standing
2 Standing unsupported
3 Sitting unsupported
4 Standing to sitting
5 Transfers
6 Standing with eyes closed
7 Standing with feet together
8 Reaching forward with outstretched arm
9 Retrieving object from ﬂoor
10 Turning to look behind
11 Turning 360
12 Placing alternate foot on stool
13 Standing with one foot in front
14 Standing on one foot
Total
Source: Berg K, Wood-Dauphinee S and Williams JI: The Balance Scale: reliability
assessment with elderly residents ans patients with an acute stroke. Scand J Rehabil
Med 1995; 27 (1): 27e36.
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The patients of the intervention group shall complete one 30-
min hippotherapy session once a week for 12 weeks according to
the guidelines for hippotherapy of the DKThR [1].
All study participants shall continue their current physiotherapy
without any change. The medication shall be kept stable over the
study period. In general, during the study no therapies shall be
stopped or initiated.
2.6. Outcomes
The primary endpoint of the study is the change in balance
function after 12 weeks of therapy (change from baseline). The
instrument used is the Berg Balance Scale (BBS) [8], which has been
considered the gold standard for the measurement of balance since
the 1990s (see Table 5).
Due to its sensitivity to change (responsiveness) and its very
good reliability, the BBS is especially suited for measurements overTable 6
Secondary outcome measures.
 Change in fatigue: Fatigue Severity Scale (FSS)
 Change in quality of life: Multiple Sclerosis Quality of Life-54 (MSQoL-54)
 Change in pain intensity: Visual Analogue Scale (VAS)
 Change in Spasticity: Numeric Rating Scale (NRS)
Table 7
Visit schedule.
Enrolment (Day 0)
Enrolment
Screening for eligibility X
Informed consent X
Allocation X
Interventions
Hippotherapy
Physiotherapy and/or pharmacotherapy
Assessment
Demographic data, medical history X
Balance function
Fatigue
Quality of life
Pain intensity
Spasticity
AEs/SAEs
End of treatment/studythe course of time. The scale is very reliable with repeated mea-
surements by the same examiners (intra-tester reliability), as well
as by two different examiners (inter-tester reliability). The imple-
mentation of this assessment takes approximately 15e20 min [9].
Secondary outcome measures are as follows: Fatigue is assessed
by the Fatigue Severity Scale (FSS), which contains 9 items. By
means of this scale, the severity of a fatigue can be shown [10]. It
allows a distinction between cognitive, affective and somatic dys-
functions. The FSS is considered to be the gold standard for vali-
dating other or new fatigue scales and is recommendable due to its
simplicity and rapid implementation [11].
TheMultiple Sclerosis Quality of Life-54 (MSQoL-54) instrument
is a disease-speciﬁc questionnaire for patients with multiple scle-
rosis which extends the generic SF-36 questionnaire with 18 MS-
speciﬁc items [12].
The change in the pain and spasticity symptoms is displayed in
the Visual Analogue Scale (VAS) [13,14] and/or the Numeric Rating
Scale (NRS) [15]. Through these simple and easy-to-use scales, the
patient can document his/her symptoms (see Table 6).
2.7. Visits and assessments
After screening by the study physicians, patients will be rand-
omised to one of the two treatment groups. The subsequently
initial assessment will take place prior to the ﬁrst hippotherapy
session or ﬁrst observation week. The interim assessment will be
carried out 6th e 7th week, the ﬁnal assessment 13 weeks after
initial assessment (see Table 7). During the assessments the
respective primary and all secondary endpoints are to be deter-
mined (duration approx. one hour). The assessments shall take
place in a separate room at the study centre or in the physiother-
apists' own premises. Since blinding of the patients is not possible
due to the nature of the intervention, the examining physiothera-
pists are to be blinded during the entire study phase to ensure an
observer-blinded endpoint assessment. Accordingly, they do not
knowwhether the respective patient is in the intervention group or
in the control group. In a central training session for the physio-
therapists, it shall be explicitly pointed out that any questioning of
the patients or the hippotherapists is prohibited. The patients shallVisit 1 (Day 1) Visit 2 (Week 6e7) Visit 3 (Week 13)
12 sessions within 12 weeks
physiotherapy and/or pharmacotherapy as prior to the study within 12 weeks
X X X
X X X
X X X
X X X
X X X
X X X
X
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conﬁdentiality.
2.8. Sample size calculation
The sample size calculation is based on the primary endpoint
change of the BBS after 12 weeks of therapy (difference between
BBS after 12 weeks and initial value of BBS). The assumptions for
the expected therapy effect are based on the results of the pre-post
pilot studies by Sager et al. (2007; n ¼ 16) [6] with an average
improvement of 5.6 points after 12 weeks, as well as the pilot study
with the control group by Schneider et al. (2010; n¼ 12) [7] with an
average improvement of 6.5 points after six weeks of hippotherapy.
Based on the standard deviations found in the two previous studies
(Sager: 8.3; Schneider: control group: 5.6; therapy group: 7.6), we
chose a conservative approach and assumed that the standard
deviation is 8.3 in both groups. Under these assumptions, at a type I
error rate of a ¼ 5% (2-sided) and a power of 1-b ¼ 80% with a
sample size of 64 (2  32), a difference of 6 points can be revealed
using the student's t test. It can be assumed that in the covariance
analysis, which is described for the evaluation of the primary
endpoint, the power is increased compared with the t test.
Assuming a drop-out rate of approximately 10%, a total 70 patients
(2  35) shall be randomised.
2.9. Screening and randomisation
Patients were consecutively informed and screened by the study
physicians, and eligible patients are included in the study. After
giving written informed consent, patients are randomly assigned to
one of the two treatment groups: the hippotherapy intervention
group or the control group. The randomisation of patients will be
stratiﬁed by centre and disability as measured with the expanded
disability status scale (EDSS) [16] (<5 vs.  5) (permuted blocks of
varying length) and implemented by sealed opaque envelopes
generated on the basis of a computer-generated randomisation list.
2.10. Data management and monitoring
Data management is to be performed using REDCap software
[17]. For infrastructural reasons in the study centres, the data shall
be collected on paper, not electronically. Inconsistencies and im-
plausibilities shall be clariﬁed in writing by the project manager
with the study centres. These queries are to be answered in a timely
manner by the study centres. The data shall be entered into the
study database by the project manager and another independent
person. A third independent person shall compare the data entries
and decide in case of discrepancies.
To ensure the quality of the study, amonitoring by the Centre for
Clinical Trials Cologne (ZKS) shall be carried out in the study cen-
tres. An initial visit shall take place in each study centre, and a
regular visit after enrolment of all patients in the respective study
centre.
2.11. Statistical analyses
The primary analysis will be performed according to the
intention to treat, i.e. all patients randomised are analyzed as
assigned.
The primary target variable is the change of the BBS (difference
between BBS after 12 weeks and initial value of BBS). The treatment
comparison is evaluated using a covariance analysis (ANCOVA) with
the baseline BBS, centre, age, gender and EDSS classiﬁcation as
covariates. Missing values shall be imputed through the last observed
value (LOCF). The stability of the results when using differentimputation methods shall be veriﬁed by sensitivity analyses. As
further sensitivity analysis, an evaluation of the course data shall be
performed by means of complex mixed-effects models (change in
BBS over the course of the study). The secondary endpoints are to be
analysed mainly descriptively. In addition, a covariance analysis in
analogy to the analysis of the primary endpoint will be done. The
safety data are to be reported and listed in summary form. Further
details are laid out in the statistical analysis plan.
Three study populations will be analysed. The primary evalua-
tion data set is the modiﬁed intention-to-treat population (modiﬁed
ITT). This data set includes all patients who were enrolled and
randomised in the clinical study and fromwhom at least the initial
value of the BBS was collected.
The secondary evaluation data set is the per-protocol population,
This data set contains all patients who were treated according to
the protocol over the entire study period, i.e. for whom no major
protocol violations were documented and who, in addition to the
initial assessment, completed at least two assessments (interim
assessment and/or ﬁnal assessment). It is considered a major pro-
tocol violation e in the case of the intervention group e if less than
9 of the 12 planned hippotherapy sessions were completed. (A
comparable deﬁnition is not possible for the control group, because
only an already ongoing physical therapy is continued individually.)
Analyses of primary and secondary endpoints will be done for
modiﬁed ITT and per-protocol population. The analysis of the per-
protocol population is considered to be a sensitivity analysis.
The tertiary evaluation data set (safety population) includes all
patients who received at least one treatment (hippotherapy or
physiotherapy). This populationwill be used for the safety analyses.
2.12. Safety assessment and reporting of adverse events
Prior to each assessment (and prior to a hippotherapy session),
the patients shall be asked whether any adverse or serious adverse
events have occurred. Adverse events are to be documented both in
the respective questionnaire forms as well as on the AE/SAE form.
Each adverse event is to be assessed by the head hippotherapist in
the centre, and if necessary by the study physician in order to
determine whether an association with the hippotherapy can be
suspected.
Adverse events will be assessed from the day of randomization
until the regular end of trial follow-up or until premature with-
drawal of a patient.
Any event with an unfavourable effect for the participant
regardless of an association to the intervention is considered an
adverse event. A serious adverse event will be deﬁned as an event
that results in death, is immediately life-threatening, requires or
prolongs hospitalization for any medical reason, or results in
persistent or signiﬁcant disability or incapacity.
Each serious adverse event will immediately be communicated
within 24 h to the study centre and to the coordinating investigator,
and the relevant ethics commission will be notiﬁed.
3. Ethical and legal aspects
The study was designed and shall be conducted according to the
principles of Good Clinical Practice (GCP, ICH E6) and data protec-
tion laws. The local ethics committees of all participating centres
approved the study protocol. The trial was registered in the German
Clinical Trial Register under DRKS00005289.
4. Discussion
Recent estimates suggest that 2.5 million people worldwide are
suffering from Multiple Sclerosis. Pharmaceutic studies cover a
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tions examined are limited. Until now there has not been any high-
quality randomised study that has examined the effectiveness of
hippotherapy. The results of this randomised clinical trial will be of
utmost relevance both to patients as well as their physicians.
However, the MS-HIPPO study design though following Good
Clinical Practice has some limitations. As the trial will be performed
in a setting and with therapists who are not regularly involved with
studies it will be a challenge. Hippotherapists and physiotherapists
will accordingly be trained to strengthen compliance with the
guidelines and to clarify the obligation of keeping the allocation of
all patients conﬁdential.
Due to the nature of the intervention, blinding of patients is not
possible. Therefore it is crucial to ensure an observer-blinded
endpoint assessment. That is, physiotherapists will be blinded
during the entire study. The importance of keeping the allocation of
all patients conﬁdential will be conveyed with emphasis to all who
are involved with the trial conduction. Physiotherapists were
repeatedly instructed not to request information on the therapeutic
regimens of the patients. Likewise the participants were informed
about the importance of blinding. Furthermore, participants of the
intervention armwere instructed to strictly conﬁne their questions
about the intervention to the respective hippotherapists. Blinding
of the examiners and a strict intention-to-treat analysis will
contribute to the quality and credibility of the upcoming study.
In view of the increasing use and relevance of hippotherapy in
the treatment of various neurological and muscular disorders, it is
of utmost relevance to investigate whether MS-patients beneﬁt
from an additional hippotherapy or not. MS-HIPPO is the ﬁrst
randomised controlled trials evaluating the effects of hippotherapy
on symptoms of MS and life quality and hence will close a gap in
research and serve patients' demands.
5. Conclusion
The trial is the ﬁrst randomised trial evaluating the beneﬁts of
hippotherapy for patients with multiple sclerosis. The expected
results will help to improve the evidence base and will allow
conclusions on the effectiveness of hippotherapy on the symptoms
of multiple sclerosis.
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